AR111699A1 - Composición farmacéutica que comprende betahistina - Google Patents

Composición farmacéutica que comprende betahistina

Info

Publication number
AR111699A1
AR111699A1 ARP180100254A ARP180100254A AR111699A1 AR 111699 A1 AR111699 A1 AR 111699A1 AR P180100254 A ARP180100254 A AR P180100254A AR P180100254 A ARP180100254 A AR P180100254A AR 111699 A1 AR111699 A1 AR 111699A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
betahistina
composition including
enhancing agent
viscosity enhancing
Prior art date
Application number
ARP180100254A
Other languages
English (en)
Inventor
Thomas Meyer
Christopher John Wraight
Original Assignee
Otolanum Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otolanum Ag filed Critical Otolanum Ag
Publication of AR111699A1 publication Critical patent/AR111699A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica para administración intranasal a un paciente humano, que comprende una solución o suspensión de una cantidad terapéuticamente eficaz de betahistina o una sal farmacéuticamente aceptable de esta y un agente potenciador de la viscosidad. Reivindicación 9: La composición farmacéutica de la reivindicación 8, donde el agente potenciador de la viscosidad es polivinil pirrolidona.
ARP180100254A 2017-02-02 2018-02-02 Composición farmacéutica que comprende betahistina AR111699A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762453931P 2017-02-02 2017-02-02

Publications (1)

Publication Number Publication Date
AR111699A1 true AR111699A1 (es) 2019-08-14

Family

ID=61187302

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100254A AR111699A1 (es) 2017-02-02 2018-02-02 Composición farmacéutica que comprende betahistina

Country Status (34)

Country Link
US (2) US10456386B2 (es)
EP (2) EP3698791B1 (es)
JP (3) JP2020506930A (es)
KR (1) KR102653545B1 (es)
CN (1) CN110418643A (es)
AR (1) AR111699A1 (es)
AU (1) AU2018216970B2 (es)
BR (1) BR112019015687A2 (es)
CA (1) CA3051725A1 (es)
CL (1) CL2019002145A1 (es)
CO (1) CO2019008657A2 (es)
DK (2) DK3698791T3 (es)
EA (1) EA201991817A1 (es)
ES (2) ES2969301T3 (es)
FI (1) FI3698791T3 (es)
HR (2) HRP20231706T1 (es)
HU (2) HUE050829T2 (es)
IL (1) IL268353B2 (es)
LT (2) LT3474850T (es)
MA (1) MA46778B1 (es)
MX (1) MX2019008961A (es)
MY (1) MY196333A (es)
NZ (1) NZ755931A (es)
PH (1) PH12019501785A1 (es)
PL (2) PL3474850T3 (es)
PT (2) PT3474850T (es)
RS (2) RS60554B1 (es)
SA (1) SA519402324B1 (es)
SG (1) SG11201906980YA (es)
SI (2) SI3698791T1 (es)
TN (1) TN2019000220A1 (es)
TW (1) TWI760429B (es)
WO (1) WO2018141922A1 (es)
ZA (1) ZA201904955B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170532A1 (en) * 2017-03-22 2018-09-27 Franz, Lilian Ann Treatment method
EP4135658A1 (en) * 2020-04-14 2023-02-22 GlaxoSmithKline Consumer Healthcare Holdings (US) LLC Nasal spray formulation with moisturizing benefits

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2397840B1 (es) 1977-07-22 1981-03-20 Cherqui Jean
IT1229237B (it) * 1989-05-08 1991-07-26 Prodotti Formenti Sali di (2-(piridil)etil) metilammina
JPH03287535A (ja) * 1990-03-31 1991-12-18 Bairon Boeki Kk プラノプロフェン水溶液
JP3203056B2 (ja) * 1992-08-13 2001-08-27 株式会社ティ・ティ・エス技術研究所 メシル酸ベタヒスチンの経皮吸収製剤用組成物および経皮吸収製剤
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
JPH10139667A (ja) * 1996-11-15 1998-05-26 Yoshitomi Pharmaceut Ind Ltd 水性液剤
EP1392262A1 (en) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
JP3555598B2 (ja) 2001-06-27 2004-08-18 株式会社村田製作所 積層型インダクタ
JP2004196676A (ja) * 2002-12-16 2004-07-15 Rohto Pharmaceut Co Ltd 点鼻剤
JP4733333B2 (ja) * 2002-12-26 2011-07-27 ライオン株式会社 点鼻剤又は洗鼻剤
DK1530965T3 (da) 2003-11-11 2006-07-17 Mattern Udo Kontrolleret frigivelsesleveringssystem til nasal applikation
BRPI0506807A (pt) * 2004-04-22 2007-05-29 Mor Research Applic Ltd método de gerenciamento de consumo de alimento e composição farmacológica
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
AU2006202950A1 (en) * 2004-04-22 2006-10-19 Mor Research Applications Ltd. Methods and Compositions for Weight Management
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
EP1789075A4 (en) 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
US20070111964A1 (en) * 2005-08-17 2007-05-17 Fleming And Company, Pharmaceuticals Vitamin B12 nasal spray and method of use
US8242148B2 (en) * 2005-12-23 2012-08-14 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
US8119668B2 (en) 2005-12-23 2012-02-21 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
JP2011507895A (ja) * 2007-12-21 2011-03-10 シェーリング−プラウ ヘルスケア プロダクツ，インコーポレイテッド オキシメタゾリンの増強された光安定化
KR20210107137A (ko) * 2008-04-21 2021-08-31 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
NZ589742A (en) * 2008-05-27 2012-06-29 Univ Melbourne Methods of treating mammals with eustachian tube dysfunctions with betahistine
AU2009302241B2 (en) * 2008-10-08 2015-10-29 Xgene Pharmaceutical Inc. GABA conjugates and methods of use thereof
US10471040B2 (en) * 2014-10-03 2019-11-12 Lachesis Biosciences Limited Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders

Also Published As

Publication number Publication date
IL268353B2 (en) 2023-10-01
RS60554B1 (sr) 2020-08-31
US20200022963A1 (en) 2020-01-23
SA519402324B1 (ar) 2023-03-16
JP2022051872A (ja) 2022-04-01
KR102653545B1 (ko) 2024-04-04
IL268353B1 (en) 2023-06-01
SI3474850T1 (sl) 2020-09-30
US10456386B2 (en) 2019-10-29
LT3698791T (lt) 2024-02-12
RS65099B1 (sr) 2024-02-29
PL3474850T3 (pl) 2020-09-21
BR112019015687A2 (pt) 2020-04-28
HUE065336T2 (hu) 2024-05-28
NZ755931A (en) 2022-07-29
HRP20201137T1 (hr) 2021-01-22
WO2018141922A1 (en) 2018-08-09
MY196333A (en) 2023-03-24
CA3051725A1 (en) 2018-08-09
PL3698791T3 (pl) 2024-04-08
PH12019501785A1 (en) 2020-07-06
SI3698791T1 (sl) 2024-05-31
LT3474850T (lt) 2020-08-10
HRP20231706T1 (hr) 2024-03-15
DK3698791T3 (da) 2024-01-15
JP2020506930A (ja) 2020-03-05
MA46778B1 (fr) 2022-08-31
PT3474850T (pt) 2020-07-27
KR20190116341A (ko) 2019-10-14
SG11201906980YA (en) 2019-08-27
CO2019008657A2 (es) 2020-01-17
EP3698791A1 (en) 2020-08-26
TN2019000220A1 (en) 2021-01-07
IL268353A (en) 2019-09-26
EP3474850A1 (en) 2019-05-01
MA46778A1 (fr) 2021-04-30
JP2024019731A (ja) 2024-02-09
EP3474850B1 (en) 2020-04-22
DK3474850T3 (da) 2020-08-03
HUE050829T2 (hu) 2021-01-28
TW201831179A (zh) 2018-09-01
EA201991817A1 (ru) 2020-01-27
PT3698791T (pt) 2024-01-12
ZA201904955B (en) 2021-05-26
FI3698791T3 (fi) 2024-01-11
US20180214432A1 (en) 2018-08-02
EP3698791B1 (en) 2023-10-25
ES2807798T3 (es) 2021-02-24
MX2019008961A (es) 2019-10-15
TWI760429B (zh) 2022-04-11
CL2019002145A1 (es) 2019-11-04
ES2969301T3 (es) 2024-05-17
AU2018216970A1 (en) 2019-08-22
AU2018216970B2 (en) 2023-12-21
CN110418643A (zh) 2019-11-05

Similar Documents

Publication Publication Date Title
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CR20180253A (es) Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
AR103215A1 (es) Composición farmacéutica que comprende plasminógeno y usos de este
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
MD3416631T2 (ro) Agenți terapeutici pentru bolile neurodegenerative
BR112017016084A2 (pt) composição e método para o tratamento da doença veno-oclusiva hepática
MX2021002321A (es) Nuevos metodos.
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
MD3359146T2 (ro) Compoziții farmaceutice și utilizări direcționate spre bolile de depozitare lizozomală
CL2019002172A1 (es) Agente terapéutico para enfermedades del hígado.
AR111699A1 (es) Composición farmacéutica que comprende betahistina
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
AR107935A1 (es) Uso del compuesto 6-(4-(2,3-dimetilfenoxi)piperidin-1-il)metil)pirimidino-2,4(1h,3h)-diona o una sal farmacéuticamente aceptable del mismo para preparar un medicamento, combinación y composición farmacéutica que comprende dicho compuesto
AR088845A1 (es) Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel
MX2023006235A (es) Composiciones para administracion de farmacos y metodos de uso de las mismas.
CO2018009543A2 (es) Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma
PE20190347A1 (es) Formulaciones inyectables fisiologicamente balanceadas de fosnetupitant